Edgar Filing: Cox John - Form 4

Cox John

Form 4									
October 29,									
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIO							OMB APPROVAL		
Check th	is box	Washington,	, D.C. 20549			Number:	3235-0287		
if no lon subject to Section	^{ger} STATEMENT 16.	OF CHANGES IN SECUR		L OW	NERSHIP OF	Expires: Estimated a burden hour			
Form 4 or Form 5 obligations may continue.responseSee Instruction 1(b).Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940									
(Print or Type	Responses)								
1. Name and A Cox John	Address of Reporting Person	2. Issuer Name and Symbol BIOGEN IDEC I		ng	5. Relationship of Reporting Person(s) to Issuer				
(Last)	(First) (Middle)	3. Date of Earliest Tr			(Check all applicable)				
· · /	DEC INC., 133 BOSTO	(Month/Day/Year)	ansaction		Director 10% Owner X_ Officer (give title Other (specify below) below) EVP Pharmaceutical Oper & Tech				
	(Street)	4. If Amendment, Da Filed(Month/Day/Year	-		 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 				
WESTON,	MA 02493				Person	ore than One Rej	porting		
(City)	(State) (Zip)	Table I - Non-D	Derivative Secur	rities Acq	uired, Disposed of,	, or Beneficiall	y Owned		
1.Title of Security (Instr. 3)	any		4. Securities A on(A) or Dispose (Instr. 3, 4 and (A)	d of (D)	5. Amount of Securities Beneficially Owned Following Reported	Ownership I Form: Direct B	Ownership		
		Code V	or Amount (D)	Price	Transaction(s) (Instr. 3 and 4)				
Common Stock	10/28/2010	M <u>(1)</u>	6,900 A	\$ 33.97	25,154.0411	D			
Common Stock	10/28/2010	S <u>(1)</u>	6,900 D	\$ 63	18,254.0411	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Cox John - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number onof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. l De Sec (In
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 33.97	10/28/2010		M <u>(1)</u>	6,900	(2)	07/28/2013	Common Stock	6,900	

Reporting Owners

Reporting Owner Name / Address	Relationships					
I State and a state	Director	10% Owner	Officer	Other		
Cox John BIOGEN IDEC INC. 133 BOSTON POST ROAD WESTON, MA 02493			EVP Pharmaceutical Oper & Tech			
Signatures						
Aras Lapinskas, Attorney in Fa John Cox	act for		10/29/2010			
**Signature of Reporting Perso	on		Date			

Explanation of Responses:

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Excercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. (1)

(2) The stock options became exercisable in four (4) equal annual installments commencing one year after the grant date of 7/28/2003.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.